SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med. 1994;154: 15763.
  • 2
    Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med. 1986;1: 1558.
  • 3
    Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract. 2001;18: 5658.
  • 4
    Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennet CL. Evaluation of conflict of interest in economic analyses of new drugs in oncology. JAMA. 1999;282: 14537.
  • 5
    Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res. 2002;2: 18.
  • 6
    ISI Journal Citation Report 2000. Available at: http://www.isinet.com/isi/. Accessed February 5, 2002.
  • 7
    N Engl J Med. 2001: 344–345: 11978 and 1–1882.
  • 8
    J Am Med Assoc. 2001;285–286: 13129 and 1–3119.
  • 9
    Abramson JH. Survey Methods in Community Medicine, 4th edn. Churchill Livingstone;1990:ch. 2.
  • 10
    International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Updated October 2001.
  • 11
    Drug Monitor, IMS Health Global Services. 2002. Available at: http://www.imshealth.com. Accessed July 17, 2002.
  • 12
    Holden C. NEJM admits breaking its own tough rules. Science. 2000;287: 1573.
  • 13
    Thompson DF. Understanding financial conflicts of interest. NEJM. 1993;329: 5736.
  • 14
    Stelfox HT, Chua G, O'Rourke K, Detsky A. Conflict of interest in the debate over calcium-channel antagonists. NEJM. 1998;338: 1016.
  • 15
    Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 Immunogen, an immunologic modifier, administered to patients infected with HIV having 300–549, X106/L CD4 counts: a randomized controlled trial. JAMA 2000;284: 2193202.
  • 16
    Dickersin K, Min Y, Meinert CL. Factors influencing publication of research results. JAMA. 1992;267: 3748.
  • 17
    Schulman K, Sulmasy DP, Roney D. Ethics, economics and the publication policies of major medical journals. JAMA. 1994;272: 1546.
  • 18
    Task Force on Financial Conflicts of Interest in Clinical Research. Protecting Subjects, Preserving Trust, Promoting Progress Policy and Guidelines for the Oversight of Individual Financial Interests in Human Subjects Research. Association of American Medical Colleges; 2001.
  • 19
    Boyd EA, Bero LA. Assessing faculty financial relationships with industry. JAMA. 2000;284: 220914.
  • 20
    Korn D. Conflicts of interest in biomedical research. JAMA. 2000;285: 22346.
  • 21
    Temptation to fudge scientific findings. The Virginian-Pilot and The Ledger-Star, Norfolk, Va. November 12, 2000.
  • 22
    Deangelis CD. Conflict of interest and the public trust. JAMA. 2000;284: 22378.
  • 23
    Friedman Ross L. Correspondence to editor in reply to “Is Academic Medicine for Sale?” NEJM. 2000;342: 508.